Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

PURPOSE: Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Hammers, Hans J., Plimack, Elizabeth R., Infante, Jeffrey R., Rini, Brian I., McDermott, David F., Lewis, Lionel D., Voss, Martin H., Sharma, Padmanee, Pal, Sumanta K., Razak, Albiruni R. Abdul, Kollmannsberger, Christian, Heng, Daniel Y.C., Spratlin, Jennifer, McHenry, M. Brent, Amin, Asim
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587408/
https://ncbi.nlm.nih.gov/pubmed/28678668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.72.1985
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares